| Video
Some further observations on the role of opioids, including advice to the primary clinician as they approach the prescribing decision.
| Video
Dr. Argoff comments on the appropriate role of opioid analgesics as part of therapy for chronic noncancer pain, with observations on protecting legitimate access while preventing abuse.
| Article
I think the important thing with methadone is safety first. Even though I’m a big methadone fan, I don’t think everyone is an ideal candidate for methadone therapy. I think we have to have a patient who’s very reliable, who will follow the plan of care, who will follow the directions, someone who...
| Video
What would the world be like without opioids? Dr. Clark hypothesizes on the implications for patients with pain, and on what the characteristics of a “better” opioid might include.
| Video
In this 2-part segment, Dr. Passik discusses some of the lessons learned during and following the Decade of Pain Control and Research, and implications for the appropriate engagement of opioid therapy in chronic noncancer pain management.
| Video
In this 2-part segment, Dr. Passik discusses some of the lessons learned during and following the Decade of Pain Control and Research, and implications for the appropriate engagement of opioid therapy in chronic noncancer pain management.
| Article
The Iceberg Cometh
Dr. Passik is Director, Clinical Addiction Research and Education, Millenium Laboratories Clinical Education, San Diego, California. He has over 25 years’ experience in clinical practice as a pain psychologist specializing in addiction medicine. He is also a longtime member of...
| Video
A discussion of the evolving medical/administrative/legal landscape that confronts prescribers of opioid medications. Attorney Furman offers additional advice on how clinicians can protect their practices.
| Video
A pharmacist perspective on the pros and cons of opioid treatment agreements.
| Article
The transdermal formulations of fentanyl and buprenorphine are for patients who have chronic pain. An important distinction is, with transdermal fentanyl the patient has to be opioid tolerant, on the equivalent of 60 mg of oral morphine a day for at least a week, whereas with transdermal...